The future role of CD4 cell count for monitoring antiretroviral therapy (Q38281773)

1 September 2017

1 reference

title

The future role of CD4 cell count for monitoring antiretroviral therapy (English)

1 reference

1 September 2017

anti-retroviral agent

0 references

8

Beatriz Grinsztejn

1 reference

1 September 2017

Graeme Meintjes

2

0 references

Alexandra Calmy

9

object named as

Alexandra Calmy

1 reference

1 September 2017

10

N Kumarasamy

1 reference

1 September 2017

7

Mary-Ann Davies

1 reference

1 September 2017

1

Nathan Ford

1 reference

1 September 2017

4

Helen Bygrave

1 reference

1 September 2017

11

Praphan Phanuphak

1 reference

1 September 2017

15

Wendy Stevens

1 reference

1 September 2017

13

Marco Vitoria

1 reference

1 September 2017

14

Meg Doherty

1 reference

1 September 2017

Anton Pozniak

3

1 reference

1 September 2017

Andrew Hill

5

1 reference

1 September 2017

Trevor Peter

6

1 reference

1 September 2017

Pierre deBeaudrap

12

1 reference

1 September 2017

George K Siberry

16

1 reference

1 September 2017

19 November 2014

1 reference

Lancet Infectious Diseases

1 September 2017

1 reference

1 September 2017

15

1 reference

1 September 2017

2

1 reference

1 September 2017

241-247

1 reference

Predictors of the acquired immunodeficiency syndrome developing in a cohort of seropositive homosexual men

1 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970896-5

7 January 2021

Effect of T4 count and cofactors on the incidence of AIDS in homosexual men infected with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970896-5

7 January 2021

The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970896-5

7 January 2021

Serial CD4 lymphocyte counts and development of AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970896-5

7 January 2021

Acquired Immunodeficiency Syndrome: Epidemiologic, Clinical, Immunologic, and Therapeutic Considerations

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970896-5

7 January 2021

Trends in survival of Danish AIDS patients from 1981 to 1989.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970896-5

7 January 2021

Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970896-5

7 January 2021

Predicting treatment failure in adults and children on antiretroviral therapy: a systematic review of the performance characteristics of the 2010 WHO immunologic and clinical criteria for virologic failure

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970896-5

7 January 2021

Viral load monitoring as a tool to reinforce adherence: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970896-5

7 January 2021

Is frequent CD4+ T-lymphocyte count monitoring necessary for persons with counts >=300 cells/μL and HIV-1 suppression?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970896-5

7 January 2021

Can we stop CD4+ testing in patients with HIV-1 RNA suppression on antiretroviral treatment?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970896-5

7 January 2021

Scaling up antiretroviral therapy in resource-limited settings: adapting guidance to meet the challenges

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970896-5

7 January 2021

Cost-effectiveness of laboratory monitoring for management of HIV treatment in sub-Saharan Africa: a model-based analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970896-5

7 January 2021

Challenges and opportunities for the implementation of virological testing in resource-limited settings

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970896-5

7 January 2021

Developments in CD4 and viral load monitoring in resource-limited settings

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970896-5

7 January 2021

Prevention of HIV-1 infection with early antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970896-5

7 January 2021

Adoption of national recommendations related to use of antiretroviral therapy before and shortly following the launch of the 2013 WHO consolidated guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970896-5

7 January 2021

Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970896-5

7 January 2021

Mortality by baseline CD4 cell count among HIV patients initiating antiretroviral therapy: evidence from a large cohort in Uganda

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970896-5

7 January 2021

Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970896-5

7 January 2021

Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970896-5

7 January 2021

Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970896-5

7 January 2021

Effect of cotrimoxazole on mortality in HIV-infected adults on antiretroviral therapy: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970896-5

7 January 2021

Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970896-5

7 January 2021

CD4 cell count changes in individuals with counts above 500 cells/mm3 and viral loads below 50 copies/ml on antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970896-5

7 January 2021

Stop routine CD4 monitoring in HIV-infected patients with fully suppressed virus and CD4 >=350 cells/ml

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970896-5

7 January 2021

Is it safe to drop CD4+ monitoring among virologically suppressed patients: a cohort evaluation from Khayelitsha, South Africa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970896-5

7 January 2021

Optimizing frequency of CD4 assays in the era of highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970896-5

7 January 2021

CD4(+) T-cell recovery after initiation of antiretroviral therapy in a resource-limited setting: a prospective cohort analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970896-5

7 January 2021

CD4 Cell Counts of 800 Cells/mm3 or Greater After 7 Years of Highly Active Antiretroviral Therapy Are Feasible in Most Patients Starting With 350 Cells/mm3 or Greater

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970896-5

7 January 2021

Immune and virological benefits of 10 years of permanent viral control with antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970896-5

7 January 2021

Characteristics, Determinants, and Clinical Relevance of CD4 T Cell Recovery to <500 Cells/ L in HIV Type 1--Infected Individuals Receiving Potent Antiretroviral Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970896-5

7 January 2021

Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970896-5

7 January 2021

Mortality associated with discordant responses to antiretroviral therapy in resource-constrained settings

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970896-5

7 January 2021

A CD4+ Cell Count <200 Cells per Cubic Millimeter at 2 Years After Initiation of Combination Antiretroviral Therapy Is Associated With Increased Mortality in HIV-Infected Individuals With Viral Suppression

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970896-5

7 January 2021

Incomplete immune recovery in HIV infection: mechanisms, relevance for clinical care, and possible solutions

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970896-5

7 January 2021

Editorial commentary: can we break the habit of routine CD4 monitoring in HIV care?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970896-5

7 January 2021

HIV-1 viral load monitoring: an opportunity to reinforce treatment adherence in a resource-limited setting in Thailand

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970896-5

7 January 2021

Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970896-5

7 January 2021

Clinical outcome of HIV-infected patients with discordant virological and immunological response to antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970896-5

7 January 2021

Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970896-5

7 January 2021

Increases in adult life expectancy in rural South Africa: valuing the scale-up of HIV treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970896-5

7 January 2021

Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970896-5

7 January 2021

Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970896-5

7 January 2021

10.1016/S1473-3099(14)70896-5

Identifiers

DOI

1 reference

release_wirztiuhtvfkzkigorr3ydyuri

1 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/wirztiuhtvfkzkigorr3ydyuri

24 November 2022

mapped directly with Wikidata item

1 reference